December 2, 2013 (Shareholders Foundation) - An investigation on behalf of investors of Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) shares over potential securities laws violations by Oncolytics Biotech, Inc. and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) concerning whether a series of statements by Oncolytics Biotech, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Oncolytics Biotech, Inc. (USA) reported that its Net Loss increased from $15.00 million in 2009 to $36.37 million in 2012.

On November 1, 2013, Oncolytics Biotech, Inc. (USA) announced data for the endpoints in its double blinded, randomized clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in patients with second-line platinum-refractory, taxane-nave head and neck cancers (REO 018). The same day an article was published with the tiel Oncolytics Biotech Shades Truth On Failed Cancer Study that alleged nine red flags.

Shares of Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) declined from $2.52 per share on November 20, 2013, to $1.641 on November 26, 2013.

On December 2, 2013, NASDAQ:ONCY shares closed at $1.73 per share.